Only by combining these two methods can you get a comprehensive picture
Scientists merged two complementary imaging techniques to visualize disease-relevant molecules at micrometer precision, enabling early detection before visible tissue damage occurs. In Fabry disease models, harmful lipids (Gb3) accumulate unevenly in heart tissue in spatially distinct clusters, explaining individual disease variation previously poorly understood.
- Researchers combined Raman microscopy with atmospheric-pressure mass spectrometry imaging to achieve micrometer-level precision
- In Fabry disease mouse models, harmful lipids (Gb3) form spatially distinct clusters rather than distributing evenly
- Next phase involves testing the technique on human Fabry disease tissue samples to develop improved diagnostics
Researchers combined Raman microscopy with mass spectrometry imaging to create high-resolution molecular maps of cardiac tissue in Fabry disease, revealing uneven lipid accumulation patterns invisible to standard microscopy.
A team of researchers at Germany's Leibniz Institute for Analytical Sciences has developed a way to see what was previously invisible: the precise location of disease-causing molecules within living tissue, before damage becomes obvious to the naked eye. By combining two imaging techniques—Raman microscopy and atmospheric-pressure mass spectrometry imaging—they created a molecular map so detailed it can reveal the position of individual lipid molecules at a resolution of just a few micrometers. The work, published in Analytical Chemistry, offers a new window into how diseases actually unfold at the cellular level.
The challenge they solved is fundamental to medicine. Doctors have long known which molecules cause disease and which organs they damage, but they've lacked a clear picture of how those molecules are actually distributed within tissue. This matters enormously. If you know a harmful lipid is accumulating somewhere in the heart, but you don't know where or in what pattern, you can't fully understand why one patient's disease progresses differently from another's. You also can't intervene precisely. The researchers used Fabry disease as their testing ground—a rare genetic metabolic disorder in which the body fails to break down certain lipids called globotriaosylceramides, or Gb3. Over time, these lipids pile up in the heart, kidneys, and other organs, causing progressive, life-threatening damage.
Raman microscopy captures the chemical fingerprint of molecular classes and tissue structure with a pixel size as small as two micrometers. Mass spectrometry imaging, by contrast, identifies and pinpoints individual molecules with high precision, down to five-micrometer pixels. Neither technique alone tells the complete story. Raman shows you the broad chemical landscape; mass spectrometry shows you the specific players. The researchers developed software that automatically merged both datasets and aligned them with micrometer-level accuracy on the same tissue section—a technical feat that required solving the problem of registering two different imaging modalities in perfect spatial alignment.
When they applied this combined approach to heart tissue from mice with Fabry disease, the molecular map revealed something unexpected and clinically important: Gb3 doesn't distribute evenly throughout the tissue. Instead, different molecular variants of Gb3 form small, spatially distinct clusters. This uneven patterning had never been visualized before. It suggests that the disease doesn't simply flood an organ uniformly; it creates localized zones of accumulation. That distinction could explain why Fabry disease manifests differently from person to person—a phenomenon that has puzzled clinicians for years. "Only by combining these two methods can you get a comprehensive picture of what's actually happening inside the tissue," said Sven Heiles, who heads the lipidomics research group at ISAS. "For reliable diagnosis, you need to know exactly where these molecules are gathering."
The researchers acknowledge that while the genetic basis of Fabry disease and elevated Gb3 levels in blood have been well documented, the fine-grained distribution of lipids at the cellular and subcellular level—and the individual variation in that distribution—has remained poorly understood. This new technique begins to fill that gap. The next phase is to test the method on actual tissue samples from Fabry disease patients, moving beyond animal models to human disease. The goal is to use these complementary imaging approaches to decode the mechanisms driving different manifestations of Fabry disease in different people, and on that foundation, to develop more targeted diagnostic and treatment strategies.
Beyond Fabry disease, the researchers see applications in other conditions where molecules undergo localized changes within tissue—cardiovascular diseases, metabolic disorders, and others where early detection and precision intervention could change outcomes. The work represents a shift in how disease can be studied: not as a global phenomenon affecting an organ, but as a spatially organized process unfolding at the molecular scale, visible now before the damage becomes irreversible.
Citações Notáveis
Only by combining Raman microscopy with mass spectrometry imaging is it possible to obtain a comprehensive picture of the molecular processes within the tissue.— Prof. Dr. Sven Heiles, Leibniz Institute for Analytical Sciences
The distribution of lipids in human tissue at the cellular and subcellular levels—as well as the associated interindividual heterogeneity—had previously been inadequately characterized.— Prof. Dr. Kristina Lorenz, Leibniz Institute for Analytical Sciences
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter where these lipid molecules are located? Isn't it enough to know they're accumulating?
Not really. If you know a toxic molecule is building up but you don't know where, you're flying blind. Different tissues might accumulate it in different patterns. One person might have clusters in the heart muscle itself; another might have it concentrated in the blood vessels feeding the heart. That difference could explain why two patients with the same genetic mutation have completely different disease trajectories.
So this technique is essentially giving you a map of where the damage is happening?
Exactly. And more than that—it's showing you the map before the damage becomes visible under a regular microscope. That's the real breakthrough. You can catch the early stages of accumulation when intervention might still help.
How did they actually merge two completely different imaging techniques?
They developed software that automatically aligned the data from both methods with micrometer precision. Raman microscopy gives you the chemical landscape; mass spectrometry identifies the specific molecules. The software stitches those two views together so they're perfectly overlaid on the same tissue section.
And what did they find in the Fabry disease tissue?
The lipids weren't spread uniformly. They formed small, spatially distinct clusters. That's never been seen before. It suggests the disease doesn't just flood an organ—it creates localized hot spots. That could explain why the disease looks different in different patients.
What happens next?
They test it on human tissue samples. If it works the same way in people as it does in mice, this could become a diagnostic tool. You could identify where lipids are accumulating in a patient's heart before serious damage occurs, and potentially target treatment to those specific zones.